Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
0.97Last Year’s EPS
0.83Same Quarter Last Year
Strong Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Mar 10, 2025
|% Change Since: -19.23%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements in revenue growth, strategic transitions, and pipeline expansion, but also acknowledged challenges such as supply interruptions, market penetration issues for LOQTORZI, and dissatisfaction with the current stock price.Company Guidance
During the Coherus BioSciences Q4 and full year 2024 earnings call, the company provided several metrics and key guidance. Coherus reported UDENYCA net sales of $46.3 million for Q4 2024, a 28% increase compared to Q4 2023, with fiscal year 2024 sales totaling $206 million, a 62% rise from the previous year. LOQTORZI net revenue for Q4 was $7.5 million, marking a 29% increase quarter-over-quarter, with fiscal year 2024 revenue at $19.1 million. The company anticipates having $250 million in cash post-UDENYCA divestiture, projecting a cash runway beyond two years. A 30% headcount reduction is expected, with 50 employees transferring to the buyer of the divestiture. Coherus also highlighted their strategic focus on maximizing revenues with LOQTORZI, expanding its indications, and advancing their proprietary pipeline, including key assets like casdozokitug and CHS-114, aiming at a potential $15 billion sales opportunity when combined with LOQTORZI.Record UDENYCA Sales Increase
UDENYCA net product sales for Q4 were $46.3 million, an increase of 28% compared to $36.2 million for Q4 2023. For fiscal year 2024, UDENYCA net sales were $206 million, an increase of 62% compared to $127.1 million for fiscal year 2023.
Successful Strategic Transition and Debt Reduction
Coherus achieved key strategic objectives including a $250 million cash position post-transaction, reducing $480 million in debt, and divesting at least $800 million in assets or commitments.
LOQTORZI Revenue Growth
LOQTORZI net revenue was $7.5 million in Q4, a 29% increase quarter-over-quarter. Net revenue for fiscal year 2024 was $19.1 million.
Promising Pipeline Acquisitions
Coherus acquired a promising pipeline through the acquisition of Surface Oncology for $40 million, including assets like the first-in-class anti-IL-27 agent, casdozokitug, and a cytolytic CCR8 antibody, CHS-114.
---
CHRS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
CHRS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Mar 10, 2025 | $1.04 | $1.05 | +0.96% |
| Nov 06, 2024 | $0.72 | $0.82 | +13.89% |
| Aug 08, 2024 | $1.29 | $1.43 | +10.85% |
| May 09, 2024 | $2.12 | $1.90 | -10.38% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Coherus Biosciences (CHRS) report earnings?
Coherus Biosciences (CHRS) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Coherus Biosciences (CHRS) earnings time?
Coherus Biosciences (CHRS) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CHRS EPS forecast?
CHRS EPS forecast for the fiscal quarter 2025 (Q1) is 0.97.
---